{"id":67632,"date":"2026-06-08T14:08:45","date_gmt":"2026-06-08T06:08:45","guid":{"rendered":"https:\/\/flcube.com\/?p=67632"},"modified":"2026-06-08T14:08:46","modified_gmt":"2026-06-08T06:08:46","slug":"junshi-biosciences-forms-strategic-jv-with-zhiyu-biomedicine-contributing-oncology-antibody-ip-and-adc-platform-for-multispecific-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67632","title":{"rendered":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) announced a strategic joint venture agreement with <strong>Shanghai Zhiyu Biomedicine Co., Ltd.<\/strong> and <strong>SHENG YAO<\/strong>, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu&#8217;s next-generation oncology pipeline.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-equity-distribution\" class=\"wp-block-heading\">Transaction Structure &amp; Equity Distribution<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Junshi Contribution<\/strong><\/td><td>RMB 53,081,100 (USD 7.8M) in-kind contribution<\/td><\/tr><tr><td><strong>Contribution Type<\/strong><\/td><td>IP rights + laboratory assets<\/td><\/tr><tr><td><strong>Angel Investment<\/strong><\/td><td>USD 15M from four investors for RMB 468,750 equity<\/td><\/tr><tr><td><strong>Post-Transaction Ownership<\/strong><\/td><td>Junshi: 14.55%<br>SHENG YAO: 34.91%<br>Founding Team\/ESOP\/Angels: 50.54%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-licensed-technology-portfolio\" class=\"wp-block-heading\">Licensed Technology Portfolio<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Antibody Technologies:<\/strong> Three undisclosed product candidates targeting solid tumors and hematological malignancies<\/li>\n\n\n\n<li><strong>ADC Platform IP:<\/strong> Comprehensive intellectual property covering antibody-drug conjugate development processes<\/li>\n\n\n\n<li><strong>Development Scope:<\/strong> Rights to create <strong>multispecific antibodies<\/strong> (trispecific or higher order), <strong>antibody X conjugates (AXC)<\/strong>, and derivative or substantially equivalent products<\/li>\n\n\n\n<li><strong>Asset Transfer:<\/strong> Laboratory equipment and development achievements related to licensed targets and products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-pipeline-implications\" class=\"wp-block-heading\">Strategic Rationale &amp; Pipeline Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Junshi&#8217;s Strategy:<\/strong> Monetizes non-core IP while maintaining strategic minority stake in emerging innovator<\/li>\n\n\n\n<li><strong>Zhiyu&#8217;s Advantage:<\/strong> Immediate access to validated oncology targets and established ADC platform accelerates preclinical timeline by 12-18 months<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Multispecific antibodies market projected to reach $25B by 2030; AXC segment represents fastest-growing conjugate modality<\/li>\n\n\n\n<li><strong>Risk Mitigation:<\/strong> In-kind contribution structure preserves Junshi&#8217;s cash position while enabling portfolio diversification<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-context\" class=\"wp-block-heading\">Competitive Landscape Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Junshi-Zhiyu JV<\/th><th>Industry Benchmarks<\/th><\/tr><\/thead><tbody><tr><td><strong>Multispecific Focus<\/strong><\/td><td>Trispecific+ antibodies<\/td><td>Predominantly bispecific (85% of pipeline)<\/td><\/tr><tr><td><strong>Conjugate Modality<\/strong><\/td><td>AXC (Antibody X Conjugate)<\/td><td>ADC (Antibody-Drug Conjugate) dominant<\/td><\/tr><tr><td><strong>IP Foundation<\/strong><\/td><td>Licensed established platform<\/td><td>De novo platform development (24-36 months)<\/td><\/tr><tr><td><strong>Capital Efficiency<\/strong><\/td><td>Asset-light model with shared infrastructure<\/td><td>Full vertical integration required<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding joint venture formation, technology licensing, and strategic investments. Actual results may differ materially due to regulatory approvals, clinical trial outcomes, competitive pressures, and market adoption of novel therapeutic modalities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688180_20260606_SIGW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688180_20260606_SIGW.\"><\/object><a id=\"wp-block-file--media-6281e650-236a-4e1a-9d9e-a2dcdba8fa51\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688180_20260606_SIGW.pdf\">688180_20260606_SIGW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688180_20260606_SIGW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6281e650-236a-4e1a-9d9e-a2dcdba8fa51\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,296],"class_list":["post-67632","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-junshi-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu&#039;s next-generation oncology pipeline.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67632\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu&#039;s next-generation oncology pipeline.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67632\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T06:08:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T06:08:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development\",\"datePublished\":\"2026-06-08T06:08:45+00:00\",\"dateModified\":\"2026-06-08T06:08:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finance\",\"Junshi Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67632#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67632\",\"name\":\"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-08T06:08:45+00:00\",\"dateModified\":\"2026-06-08T06:08:46+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu's next-generation oncology pipeline.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67632\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67632#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu's next-generation oncology pipeline.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67632","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu's next-generation oncology pipeline.","og_url":"https:\/\/flcube.com\/?p=67632","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T06:08:45+00:00","article_modified_time":"2026-06-08T06:08:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67632#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67632"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development","datePublished":"2026-06-08T06:08:45+00:00","dateModified":"2026-06-08T06:08:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67632"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finance","Junshi Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67632#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67632","url":"https:\/\/flcube.com\/?p=67632","name":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-08T06:08:45+00:00","dateModified":"2026-06-08T06:08:46+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement with Shanghai Zhiyu Biomedicine Co., Ltd. and SHENG YAO, the legal representative of Zhiyu Bio. Junshi will subscribe for RMB 250,000 (USD 36,860) in additional registered capital through an in-kind contribution valued at RMB 53,081,100 (USD 7,826,567), comprising intellectual property rights and physical assets to accelerate Zhiyu's next-generation oncology pipeline.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67632#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67632"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67632#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67632"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67632\/revisions"}],"predecessor-version":[{"id":67634,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67632\/revisions\/67634"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}